1. Home
  2. TOPS vs BIAF Comparison

TOPS vs BIAF Comparison

Compare TOPS & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Ships Inc.

TOPS

TOP Ships Inc.

HOLD

Current Price

$0.74

Market Cap

4.9M

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$5.03

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOPS
BIAF
Founded
2000
2014
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
4.5M
IPO Year
2004
2022

Fundamental Metrics

Financial Performance
Metric
TOPS
BIAF
Price
$0.74
$5.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
121.4K
1.8M
Earning Date
04-01-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,900,000.00
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
$2.14
N/A
Revenue Growth
N/A
14.49
52 Week Low
$0.62
$0.23
52 Week High
$7.40
$13.50

Technical Indicators

Market Signals
Indicator
TOPS
BIAF
Relative Strength Index (RSI) 44.20 79.87
Support Level $0.73 $0.96
Resistance Level $0.87 $5.38
Average True Range (ATR) 0.06 0.19
MACD -0.00 0.55
Stochastic Oscillator 5.19 80.41

Price Performance

Historical Comparison
TOPS
BIAF

About TOPS TOP Ships Inc.

TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco-tanker vessels, focusing on the transportation of crude oil, petroleum products (both clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements. The company operates in two reportable segments: (i) the tanker segment and (ii) the megayacht segment.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: